Hogan Lovells advises Angelini Pharma as it acquires Catalyst Pharmaceuticals for US$4.1 billion

International pharmaceutical business Angelini Pharma S.p.A. (“Angelini Pharma”) has received advice from global law firm Hogan Lovells on its impending acquisition of Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX) for US$31.50 per share in cash, for a total equity value of roughly US$4.1 billion.